Difficulty: Medium
Average Score: 78%
Practice
Which one of the following ß- blockers has reduced risk of bronchospasm?
Correct answer
B
Rationale
The correct answer is B) Atenolol. Atenolol is a cardioselective ß-blocker, meaning it has a higher affinity for ß1 receptors in the heart compared to ß2 receptors in the lungs. This cardioselectivity results in a reduced risk of bronchospasm, making it a preferred choice in patients with respiratory conditions like asthma or COPD.
Propranolol (option A) is a non-selective ß-blocker, which blocks both ß1 and ß2 receptors. Blocking ß2 receptors can lead to bronchoconstriction and exacerbate conditions like asthma, hence increasing the risk of bronchospasm.
Pindolol (option C) is a non-selective ß-blocker similar to propranolol, so it does not offer a reduced risk of bronchospasm.
Choosing the correct ß-blocker based on its selectivity is crucial in clinical practice to minimize adverse effects and optimize therapeutic outcomes. Understanding the pharmacological properties of different medications helps healthcare providers make informed decisions tailored to individual patient needs, ensuring safe and effective treatment strategies.
Propranolol (option A) is a non-selective ß-blocker, which blocks both ß1 and ß2 receptors. Blocking ß2 receptors can lead to bronchoconstriction and exacerbate conditions like asthma, hence increasing the risk of bronchospasm.
Pindolol (option C) is a non-selective ß-blocker similar to propranolol, so it does not offer a reduced risk of bronchospasm.
Choosing the correct ß-blocker based on its selectivity is crucial in clinical practice to minimize adverse effects and optimize therapeutic outcomes. Understanding the pharmacological properties of different medications helps healthcare providers make informed decisions tailored to individual patient needs, ensuring safe and effective treatment strategies.